TNF and inflammatory bowel disease: The rising incidence and prevalence of IBD in India, coupled with increasing complexity of disease phenotypes and availability of biosimilar versions of anti-TNF, will improve access to therapy making a compelling argument to optimize available therapies to enable best possible patient outcomes.